In just a few days, Obesity Week 2024 will kick off in San Antonio, Texas.
In fact, the “preeminent international conference for obesity researchers and clinicians, Obesity Week is home to the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention, and the latest efforts in advocacy and public policy,” says The Obesity Society.
It’s also where some of the top obesity companies will present their latest data.
Look at Viking Therapeutics (SYM: VKTX), for example.
The company is set to provide results from its Phase 2 VENTURE clinical trial with its subcutaneous formulation of VK2735. It’s other presentation will highlight results from its Phase 1 multiple ascending dose clinical trial of its oral formulation of VK2735.
From its last traded price of $73.35, we’d like to see VKTX rally back above $90 a share.